Key Developments: Agenus Inc (AGEN.PH)

AGEN.PH on Philadelphia Stock Exchange

3.98USD
19 Dec 2014
Price Change (% chg)

$0.09 (+2.31%)
Prev Close
$3.89
Open
$4.10
Day's High
$4.16
Day's Low
$3.92
Volume
4,606
Avg. Vol
1,441
52-wk High
$5.21
52-wk Low
$2.28

Search Stocks

Latest Key Developments (Source: Significant Developments)

Agenus Inc's 4AB enters into a License Agreement with the Ludwig Institute for Cancer Research Ltd - Form 8-K
Thursday, 11 Dec 2014 08:01am EST 

Agenus Inc:Says, on Dec. 05, it’s wholly-owned subsidiary, 4-Antibody AG (4AB), entered into a License Agreement with the Ludwig Institute for Cancer Research Ltd., which replaces and supersedes Collaborative Research and Development Agreement entered into between parties on May 23, 2011.Pursuant to terms of License Agreement, Ludwig granted 4AB an exclusive, worldwide license under certain intellectual property rights of Ludwig and Memorial Sloan Kettering Cancer Center arising from Prior Agreement to further develop and commercialize GITR, OX-40 and TIM-3 antibodies.Pursuant to License Agreement, 4AB is obligated to make an upfront payment of $1 million to Ludwig.License Agreement also obligates 4AB to make potential milestone payments of up to $20 mln for events prior to regulatory approval of licensed products.And potential payments in excess of $80 mln if licensed products are approved in multiple jurisdictions, in more than one indication, and certain sales milestones are achieved.4AB will also be obligated to pay low to mid-single digit royalties on all net sales of licensed products during the royalty period, and to pay Ludwig a percentage of any sublicensing income, ranging from a low to mid-double digit percentage depending on various factors.  Full Article

Agenus Inc files for secondary public offerings
Thursday, 9 Oct 2014 08:00pm EDT 

Agenus Inc:Offers amount of $150,000,000 to be listed on Nasdaq SmallCap Market.  Full Article

Agenus Inc vaccine shows significant reduction in Viral Burden after HerpV Generated Immune Activation
Thursday, 26 Jun 2014 07:00am EDT 

Agenus Inc:Promising Phase 2 results for HerpV, a synthetic vaccine candidate for treatment of patients with genital Herpes Simplex Virus-2 (HSV-2).HerpV contains a defined mixture of peptides representing HSV-2 antigens plus Agenus' QS-21 Stimulon adjuvant.Says In a randomized, Phase 2, double-blind, multi-center study, the majority of patients showed an immune response to the HSV antigens after a series of vaccinations and a booster dose at six months.More than half of those vaccinated developed a robust anti-HSV cytotoxic T-cell immune response, and in those patients there was a statistically significant 75 pct reduction in viral load (P<0.001; CI: 46.2 - 88.6 pct).This level of reduction in viral load has the potential to result in reduced incidence and severity of herpetic outbreaks and reduction in viral transmission.After booster shot, HerpV demonstrated a durable reduction in viral shedding approximating 14 pct (RR=0.86 and CIs: 0.58-1.26) and remains consistent with reduction in viral shedding observed during the initial treatment period.Says protocol defined secondary analyses were viral load and viral shedding after the booster shot, primary endpoint of the study was reported in November 2013.  Full Article

Agenus Inc announces collaboration and license agreement with Merck
Monday, 28 Apr 2014 07:00am EDT 

Agenus Inc:Enters into collaboration and license agreement with Merck, known as MSD outside United States and Canada, through subsidiary, for discovery and development of therapeutic antibodies to immune checkpoints for the treatment of cancer.Agenus will discover and optimize fully human antibodies against two undisclosed Merck checkpoint targets using 4-Antibody Retrocyte Display platform.Merck will be responsible for clinical development and commercialization of candidates generated under the collaboration.Agenus is eligible to receive about $100 mln in potential payments associated with the completion of certain clinical, regulatory and commercial milestones for two candidates from Merck.In addition, Agenus is eligible to receive royalty payments on worldwide product sales.  Full Article

Agenus Inc completes acquisition of 4-Antibody
Thursday, 13 Feb 2014 07:00am EST 

Agenus Inc:Completes the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company.Agenus acquired all outstanding stock of 4-Antibody for about 3.3 million shares of Agenus common stock, plus additional contingent payments, payable in cash or Agenus common stock, that may exceed $40 million based on the combined company achieving certain milestones.  Full Article

Agenus Inc announces closing of public offering and exercise of over-allotment option
Monday, 10 Feb 2014 10:01am EST 

Agenus Inc:Closes underwritten registered public offering of common stock.Says common stock sold was 22,236,000, composed of 19,335,653 shares of common stock initially offered and an additional 2,900,347 shares of common stock sold pursuant to the exercise of the underwriters' over-allotment option, in each case at a public offering price of $2.70 per share.Says all of the shares in the offering were sold by Agenus.Net proceeds to agenus from the offering, after deducting underwriting discounts and commissions and estimated offering expenses, are about $56.0 million.William Blair & Company, L.L.C. acted as sole book-running manager for the offering.Maxim Group LLC acted as lead manager and H.C. Wainwright & Co., LLC and MLV & Co. LLC acted as co-managers for the offering.Geller Biopharm Inc. acted as financial advisor for the offering.  Full Article

Agenus Inc prices public offering of common stock
Wednesday, 5 Feb 2014 09:31am EST 

Agenus Inc:Says the pricing of an underwritten public offering of 19,335,653 primary shares of its common stock at a price of $2.70 per share.Says it has granted the underwriters a 30-day option to purchase up to 2,900,347 additional shares of common stock to cover over-allotments, if any.Says William Blair & Company, L.L.C. is acting as sole book-running manager for the offering.William Blair & Company, L.L.C. is acting as sole book-running manager for the offering.  Full Article

Agenus Inc announces public offering of common stock
Tuesday, 4 Feb 2014 05:05pm EST 

Agenus Inc:Says it has commenced an underwritten public offering of shares of its common stock.Says William Blair & Company, L.L.C. is acting as sole book-running manager for the offering.Says the shares will be issued by Agenus pursuant to a shelf registration statement that was previously filed with, and declared effective by, the SEC.  Full Article

Agenus Inc announces phase 2 checkpoint inhibitor combination trial with prophage cancer vaccine for melanoma
Tuesday, 14 Jan 2014 07:00am EST 

Agenus Inc:Says initiation of a randomized Phase 2 trial with Prophage for melanoma, and Bristol-Myers Squibb's Yervoy (ipilimumab) for the treatment of Stage III and IV metastatic melanoma.Says the combination has the potential to trigger a more effective immune response against the tumor than Yervoy alone.  Full Article

Agenus Inc enters into definitive agreement to acquire privately held 4-Antibody AG
Monday, 13 Jan 2014 07:00am EST 

Agenus Inc:Says it has entered into a definitive agreement to acquire 4-Antibody AG, a private European-based biopharmaceutical company.Says Agenus has agreed to acquire all of the outstanding stock of 4-Antibody for an initial payment of $10 million in shares of Agenus common stock, plus additional contingent payments, payable in cash or Agenus common stock, that may exceed $40 million.Says the transaction is expected to be completed by the end of Feb. 2014.  Full Article

Search Stocks